laventatug tivedotin

{
  "id": "MLC-T-ONC-014724",
  "term": "laventatug tivedotin",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC) composed of laventatug, a humanized monoclonal antibody directed against solute carrier family 39 zinc transporter member 6 (SLC39A6; LIV-1; ZIP6) that is conjugated, via a linker, to the cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration and binding to LIV-1-positive tumor cells, laventatug tivedotin enters the tumor cell lysosome through endocytosis, and releases MMAE. MMAE binds to and inhibits tubulin polymerization, which may result in G2/M phase cell cycle arrest and apoptosis in LIV-1-expressing tumor cells. LIV-1, a multi-pass transmembrane protein and zinc transporter, is expressed in several types of solid tumors and plays a key role in tumor cell progression, proliferation and metastasis. The conjugation method and linkage system prevent MMAE from separating from the antibody during circulation, thereby limiting off target toxicity.",
  "synonyms": [
    "anti-LIV-1 ADC BRY812",
    "anti-LIV-1/MMAE ADC BRY812",
    "anti-LIV-1 antibody-drug conjugate BRY812"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/laventatug-tivedotin/"
}